Roche receives EU approval of TECENTRIQ® (atezolizumab) in specific metastatic lung cancer
Roche announced the EC has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for reatment of people with locally advanced or metastatic non-small cell lung cancer after they have been previously treated with chemotherapy regardless of PD-L1 status. September 22, 2017